| Literature DB >> 36159309 |
Liming Liu1, Yue Xu1,2, Jingfei Yu1, Xiaowei Man1, Yan Jiang1, Liying Zhao1, Wei Cheng1,3.
Abstract
Objectives: To curb the unreasonable growth of medical expenses and reduce the burden of medical treatment, Beijing launched two rounds of comprehensive reform of public hospitals. In the two reforms, the addition of drugs and consumables was canceled successively. This study compared the changes in the direct medical cost of inpatients with coronary heart disease (CHD) in the three stages of two comprehensive public hospital reforms in Beijing and provides data support for health reform policies. Setting: CHD diagnosis and treatment data were extracted from the Hospital Information System (HIS) of 33 public hospitals. The total amount and composition of the direct medical expenses of CHD inpatients in the three stages were calculated. Interrupted time series analysis was used to study the instantaneous changes and trend changes in the three stages. Participants: The data were obtained from the HIS system of 33 public hospitals above the second level in Beijing. A total of 66,647 medical and diagnosis records and 24,371,139 charge detail records were included.Entities:
Keywords: comprehensive reform; coronary heart disease; direct medical expenses; inpatients; interrupted time series analysis
Mesh:
Year: 2022 PMID: 36159309 PMCID: PMC9500355 DOI: 10.3389/fpubh.2022.891186
Source DB: PubMed Journal: Front Public Health ISSN: 2296-2565
Reform measures at public hospitals in Beijing.
|
|
|
|
|---|---|---|
| Zero mark-ups on sales of drugs and medical consumables | All public hospitals canceled the increase in drug sales (excluding Chinese herbal medicine pieces). | The medical consumables markup will be canceled, and medical institutions will charge the purchase price of medical consumables and will not sell them at a higher price. |
| Medical consultation service fees | Abolition of registration fees, medical treatment fees, and the establishment of medical consultation service fees. Medical consultation service fees are priced according to the institutional and physician-level gradient. For example, the consultation service fee for general physicians in primary medical and health institutions is 20 yuan, and the consultation service fee for well-known experts in tertiary hospitals is 100 yuan. | None |
| Adjustment of the price | Adjust the price and content of 435 medical services. Among them, the prices of examinations using large-scale equipment such as computed tomography (CT) and nuclear magnetic resonance decreased, and the price of some technical services such as surgery and acupuncture increased. | Reduce the price of some large-scale equipment inspection items. Increase the prices of five types of items, including traditional Chinese medicine, pathology, spirituality, rehabilitation, and surgery, which reflect the value of medical personnel's technical labor services. |
| Procurement of medicine and medical consumables | All medical institutions can negotiate, follow bids, and purchase on the Sunshine Procurement Platform. | Implement joint procurement of medical consumables and volume-based procurement of medicine. |
| Availability of medicine | The primary medical and health institutions are provided with drugs for the stable period of four chronic diseases including hypertension, diabetes, coronary heart disease, and cerebral apoplexy, and the prescription period of eligible patients in primary medical and health institutions is extended to 2 months. | None |
Fee explanation list.
|
|
|
|---|---|
| Cost of medical consultation services | Refers to the expenses incurred from medical-technical services provided by medical personnel, which are the total expenses of the patient's hospitalization expenses after excluding examination expenses, laboratory expenses, drug expenses, and consumables expenses. |
| Cost of inspection | Refers to the relevant fees for examining, diagnosing, and treating patients using CT, MRI, and other equipment. |
| Cost of laboratory | Refers to the costs related to laboratory tests performed by patients during hospitalization, including routine blood and urine tests. |
| Cost of medicine | Refers to the cost of medicine used by the patients for the treatment of diseases, including Western medicine and traditional Chinese medicine. |
| Cost of consumables | Refers to the cost of separately chargeable medical consumables consumed by a patient during hospitalization. |
Characteristics of patients in the three reform stages.
|
|
|
| |
|---|---|---|---|
|
| 16,511 | 29,756 | 5,684 |
| Gender ( | |||
| Male | 9,892 (59.91) | 16,891 (56.77) | 3,119 (54.87) |
| Female | 6,619 (40.09) | 12,865 (43.23) | 2,565 (45.13) |
| Age, years (mean, SD) | 65.31 (11.91) | 66.21 (11.97) | 66.30 (12.22) |
| Age group ( | |||
| ≤ 39 | 192 (1.16) | 342 (1.15) | 98 (1.72) |
| 40–49 | 1,269 (7.69) | 2,010 (6.75) | 343 (6.03) |
| 50–59 | 3,875 (23.47) | 6,307 (21.20) | 1,200 (21.11) |
| 60–69 | 5,364 (32.49) | 9,880 (33.20) | 1,845 (32.46) |
| 70–79 | 3,540 (21.44) | 6,555 (22.03) | 1,272 (22.38) |
| ≥80 | 2,271 (13.75) | 4,662 (15.67) | 926 (16.29) |
| Hospital days (mean,SD) | 7.01 (5.11) | 7.79 (5.70) | 7.67 (5.00) |
| Hospital days grouping ( | |||
| ≤ 7 | 11,414 (69.13) | 17,861 (60.02) | 3,454 (60.77) |
| >7 | 5,097 (30.87) | 11,895 (39.98) | 2,230 (39.23) |
| ICD-10 code ( | |||
| I20.0 | 4,545 (27.53) | 12,821 (43.09) | 2,907 (51.14) |
| I21.4 | 1,398 (8.47) | 2,252 (7.57) | 384 (6.76) |
| I25.1 | 10,568 (64.01) | 14,683 (49.34) | 2,393 (42.10) |
| Treatment ( | |||
| Medical treatment | 11,525 (69.80) | 22,024 (74.02) | 4,153 (73.06) |
| PCI | 4,689 (28.40) | 6,609 (22.21) | 1,176 (20.69) |
| CABG | 297 (1.80) | 1,123 (3.77) | 355 (6.25) |
1. SD refers to standard deviation. 2. I20.0 refers to unstable angina pectoris; I21.4 refers to acute subendocardial myocardial infarction; I25.1 refers to arteriosclerotic heart disease. 3. PCI refers to percutaneous coronary intervention; CABG refers to coronary artery bypass grafting.
Average total cost of inpatients with coronary heart disease in three stages of different treatment methods and clinical types [1,000 RMB (1,000 dollars)].
|
|
|
|
|
|
|
|---|---|---|---|---|---|
| Medical treatment | I20.0 | 5.73 (1.55) | 5.77 (1.68) | 5.18 (1.46) | −9.62 |
| I21.4 | 9.18 (2.48) | 10.27 (3) | 8.5 (2.4) | −7.37 | |
| I25.1 | 6.92 (1.87) | 6.65 (1.94) | 6.45 (1.82) | −6.78 | |
| PCI | I20.0 | 32.17 (8.7) | 31 (9.05) | 28.16 (7.93) | −12.46 |
| I21.4 | 36.13 (9.77) | 34.91 (10.19) | 30.98 (8.73) | −14.26 | |
| I25.1 | 32.76 (8.86) | 32.9 (9.6) | 35.43 (9.98) | 8.15 | |
| CABG | I20.0 | 70.13 (18.97) | 56.32 (16.44) | 64.31 (18.12) | −8.30 |
| I21.4 | 79.05 (21.38) | 72.37 (21.12) | 99.8 (28.12) | 26.25 | |
| I25.1 | 60.55 (16.38) | 59.71 (17.43) | 62.33 (17.56) | 2.93 |
1. PCI refers to percutaneous coronary intervention; CABG refers to coronary artery bypass grafting. 2. I20.0 refers to unstable angina pectoris; I21.4 refers to acute subendocardial myocardial infarction, I25.1 refers to arteriosclerotic heart disease.
Figure 1Composition of the total cost of inpatients with different clinical types of coronary heart disease treated by medical treatment in the three reform stages (%).
Figure 2Composition of the total cost of inpatients with different clinical types of coronary heart disease treated with percutaneous coronary intervention (PCI) in the three reform stages (%).
Figure 3Composition of the total cost of inpatients with different clinical types of coronary heart disease treated with coronary artery bypass grafting (CABG) in three reform stages (%).
Figure 4ITSA of the average total cost of inpatients with coronary heart disease with different treatment methods and clinical types.
ITSA regression results of hospital costs in CHD patients with different treatment methods and clinical types.
|
|
|
|
| |||
|---|---|---|---|---|---|---|
|
|
|
|
|
| ||
| Medical treatment | I20.0 | −15.49 | 1,068.81 | 10.7 | −1,587.77 | 272.58 |
| (−0.32) | (2.08)* | −0.2 | (−1.96)· | −1.41 | ||
| I21.4 | −126.25 | 4,437.82 | 270.7 | −5,118.63 | −128.34 | |
| (−0.92) | (3.46)** | (2.07)* | (−2.52)* | (−0.27) | ||
| I25.1 | 66.48 | −594.53 | −25.36 | 117.04 | −211.57 | |
| (2.73)** | (−2.36)* | (−1.03) | −0.18 | (−1.26) | ||
| PCI | I20.0 | 200.35 | 5,228.68 | −544.15 | −10,777.18 | 4,126.77 |
| −0.77 | (1.88)· | (−1.88)· | (−2.55)* | (4.07)*** | ||
| I21.4 | −383.95 | 8,918.85 | 143.52 | −14,309.34 | 2,246.69 | |
| (−3.61)*** | (19.09)*** | −1.122 | (−7.30)*** | (3.49)** | ||
| I25.1 | −86.55 | 1,411.11 | 622.94 | −8,195.19 | −256.54 | |
| (−0.41) | −0.66 | (2.94)** | (−2.05)* | (−0.26) | ||
| CABG | I20.0 | −1,386.05 | 20,770.8 | −103.49 | 14,354.57 | 6,561.65 |
| (−1.62) | (2.45)* | (−0.12) | −1.33 | (2.30)* | ||
| I21.4 | −5,427.76 | 22,338.28 | 5,981.65 | 75,031.14 | −17,520.13 | |
| (−2.91)** | −1.11 | (2.99)** | (2.12)* | (−2.05)* | ||
| I25.1 | 2,613.08 | −9,633.27 | −3,044.34 | 2,987.14 | 4,292.28 | |
| (2.55)* | (−0.89) | (−2.62)* | −0.19 | −1.14 | ||
1. The values outside the brackets are the amount of change, and the values in the brackets are the t-values. 2. ***, **, *, and · are significant at 0.001, 0.01, 0.05, and 0.1, respectively. If not marked, the p-value is > 0.1. 3. I20.0 refers to unstable angina pectoris; I21.4 refers to acute subendocardial myocardial infarction; I25.1 refers to arteriosclerotic heart disease. 4. PCI refers to percutaneous coronary intervention; CABG refers to coronary artery bypass grafting.